Predictive markers guiding choice of therapy are yet rare and even with the most frequent mutations in CLL, affecting SF3B1, NOTCH1 and ATM, the impact on clinical decisions is modest. This evidence concerns the gene SF3B1 and B-cell chronic lymphocytic leukemia.